Amlenetug Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving Amlenetug Growth

1. Significant Unmet Need in Multiple System Atrophy (MSA)

Amlenetug is being developed for Multiple System Atrophy (MSA), a rare, progressive, and fatal neurodegenerative disorder with no approved disease-modifying therapies worldwide. Current treatment is limited to symptomatic management, leaving a substantial therapeutic gap. Patients typically survive only 6-10 years after symptom onset, highlighting the urgent need for therapies capable of slowing disease progression. If approved, amlenetug could become the first disease-modifying therapy for MSA, providing strong first-to-market advantages and premium orphan-drug pricing potential.

2. Novel Disease-Modifying Mechanism with First-in-Class Potential

Unlike symptomatic treatments, amlenetug is a human monoclonal antibody targeting extracellular a-synuclein, the pathological protein believed to drive MSA progression. By binding multiple forms of extracellular a-synuclein, the antibody is designed to inhibit pathological protein spread and enhance immune-mediated clearance through microglia. This mechanism directly addresses disease biology rather than symptoms, differentiating amlenetug from existing therapies and positioning it as a potential first-in-class treatment if efficacy is confirmed in Phase III studies.

3. Encouraging Clinical Evidence Supporting Phase III Development

Although the Phase II AMULET trial did not meet its primary endpoint, it generated clinically encouraging signals. Across all treated patients, amlenetug demonstrated approximately 19% slower clinical progression versus placebo based on the Unified Multiple System Atrophy Rating Scale (UMSARS). Importantly, patients with less advanced disease (baseline UMSARS Part I <=16) experienced approximately 37% slower disease progression, suggesting greater benefit when treatment is initiated earlier. The therapy also showed favorable MRI trends and an acceptable safety profile, providing sufficient evidence for advancement into the pivotal MASCOT Phase III trial.

4. Multiple Regulatory Designations Reduce Development Risk

Amlenetug has received several important regulatory incentives that improve its commercial prospects. These include FDA Orphan Drug Designation (2024), FDA Fast Track Designation (2025), EMA Orphan Drug Designation, and SAKIGAKE designation in Japan. These programs offer benefits such as enhanced regulatory interaction, potential rolling review, development support, market exclusivity following approval, and potentially accelerated regulatory timelines, collectively improving the probability of efficient commercialization.

5. Robust Global Phase III Program Demonstrates Development Confidence

Lundbeck's ongoing MASCOT Phase III trial (NCT06706622) represents one of the largest global MSA studies conducted to date, enrolling more than 300 patients across North America, Europe, Asia, and Australia. In March 2026, Lundbeck announced that patient randomization was completed ahead of schedule, reflecting strong investigator engagement and efficient execution. The trial incorporates innovative Bayesian progression modeling and adaptive statistical methods designed specifically for rare diseases, potentially strengthening the regulatory package if efficacy is demonstrated.

6. Commercial Opportunity Despite Rare Disease Population

Although MSA affects relatively few patients (estimated prevalence of roughly 2-5 cases per 100,000 population), orphan neurological therapies frequently achieve substantial revenues because of high annual treatment costs, long treatment duration, and limited competition. If Phase III data are positive and global approvals are obtained, amlenetug could establish a dominant position in the MSA market with minimal direct competition. Nevertheless, Lundbeck has not publicly disclosed any revenue guidance or peak sales forecast, and therefore any specific sales projections would be speculative. Commercial performance will primarily depend on successful Phase III outcomes, regulatory approvals, reimbursement decisions, physician adoption, and expansion into additional a-synucleinopathies in the future.

Amlenetug Recent Developments

In February 2025, The FDA granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). Lundbeck has recently initiated MASCOT, a phase III trial to assess efficacy and safety of amlenetug for the treatment of MSA.

"Amlenetug Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Amlenetug for potential indication like Multiple system atrophy in the 7MM. A detailed picture of Amlenetug's existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Amlenetug for potential indications. The Amlenetug market report provides insights about Amlenetug's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Amlenetug performance, future market assessments inclusive of the Amlenetug market forecast analysis for potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Amlenetug sales forecasts, along with factors driving its market.

Amlenetug Drug Summary

Amlenetug (development code Lu AF82422) is an investigational fully human IgG1 monoclonal antibody being developed by H. Lundbeck A/S under a research and licensing collaboration with Genmab for the treatment of Multiple System Atrophy, with earlier development also explored in Parkinson's disease. The antibody selectively recognizes and binds all major extracellular forms of a-synuclein, particularly aggregated species, with the aim of preventing their neuronal uptake, inhibiting pathological seeding and propagation, and promoting immune-mediated clearance through microglial Fc receptor engagement, thereby addressing the underlying neurodegenerative process rather than only relieving symptoms. Amlenetug is administered as an intravenous infusion and has demonstrated robust target engagement and favorable tolerability in Phase I studies, while the Phase II AMULET trial provided encouraging signals of disease-modifying activity, particularly in patients with less advanced disease, despite not meeting its primary endpoint in the overall study population. Based on these findings, the drug has advanced into the global Phase III MASCOT trial for MSA and has received multiple regulatory incentives, including Orphan Drug Designation in the United States, Europe, and Japan, as well as FDA Fast Track Designation, reflecting the high unmet medical need for disease-modifying therapies in MSA. The report provides Amlenetug's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Amlenetug Market Report

The report provides insights into:

• A comprehensive product overview including the Amlenetug MoA, description, dosage and administration, research and development activities in potential indication like Multiple system atrophy.
• Elaborated details on Amlenetug regulatory milestones and other development activities have been provided in Amlenetug market report.
• The report also highlights Amlenetug's cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Amlenetug market report also covers the patents information, generic entry and impact on cost cut.
• The Amlenetug market report contains current and forecasted Amlenetug sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Amlenetug market report also features the SWOT analysis with analyst views for Amlenetug in potential indications.

Methodology:

The Amlenetug market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Amlenetug Analytical Perspective by DelveInsight

• In-depth Amlenetug Market Assessment

This Amlenetug sales market forecast report provides a detailed market assessment of Amlenetug for potential indication like Multiple system atrophy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Amlenetug sales data uptil 2034.

• Amlenetug Clinical Assessment

The Amlenetug market report provides the clinical trials information of Amlenetug for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Amlenetug Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Amlenetug Market Potential & Revenue Forecast

• Projected market size for the Amlenetug and its key indications
• Estimated Amlenetug sales potential (Amlenetug peak sales forecasts)
• Amlenetug Pricing strategies and reimbursement landscape

Amlenetug Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Amlenetug Market positioning compared to existing treatments
• Amlenetug Strengths & weaknesses relative to competitors

Amlenetug Regulatory & Commercial Milestones

• Amlenetug Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Amlenetug Clinical Differentiation

• Amlenetug Efficacy & safety advantages over existing drugs
• Amlenetug Unique selling points

Amlenetug Market Report Highlights

• In the coming years, the Amlenetug market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Amlenetug companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Amlenetug's dominance.
• Other emerging products for Multiple system atrophy are expected to give tough market competition to Amlenetug and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Amlenetug in potential indications.
• Analyse Amlenetug cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Amlenetug sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Amlenetug in potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Amlenetug? How strong is Amlenetug's clinical and commercial performance?
• What is Amlenetug's clinical trial status in each individual indications such as Multiple system atrophy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Amlenetug Manufacturers?
• What are the key designations that have been granted to Amlenetug for potential indications? How are they going to impact Amlenetug's penetration in various geographies?
• What is the current and forecasted Amlenetug market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Amlenetug in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Amlenetug for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Amlenetug? What is the duration of therapy and what are the geographical variations in cost per patient?